CAMBRIDGE, England

剑桥，英格兰

,

，

March 17, 2026

2026年3月17日

/PRNewswire/ --

/PRNewswire/ --

Sequential

顺序的

, a leader in genomic testing from non-invasive human clinical samples, today announced the successful close of its first equity round, securing $3.5 million.

，一家从非侵入性人体临床样本进行基因组测试的领导者，今天宣布成功完成了其首轮股权融资，获得了350万美元。

The round was co-led by Sparkfood and Corundum Systems Biology (CSB), with participation from Dermazone Holdings, SOSV, Scrum Ventures, an ex-General Partner at Index Ventures, alongside continued support from Innovate UK. With this raise, Sequential has secured a total of $7.5M in dilutive and non-dilutive funding to date..

本轮融资由 Sparkfood 和 Corundum Systems Biology（CSB）共同领投，Dermazone Holdings、SOSV、Scrum Ventures、Index Ventures 前普通合伙人以及 Innovate UK 的持续支持参与。此次融资后，Sequential 迄今已获得总计 750 万美元的稀释性和非稀释性资金。

Continue Reading

继续阅读

Dr Oliver Worsley, Petronille Houdart, and Dr Albert Dashi of Sequential

Sequential的奥利弗·沃斯利博士、佩特罗尼尔·胡达特和阿尔伯特·达希博士

Sequential advances innovation in skin health by quantifying how ingredients and consumer, biotech, and pharmaceutical products alter microbial and host biomarkers, using their proprietary non-invasive testing platform. Its testing platform helps to transform complex biological data into clear, actionable insights.

Sequential 通过量化成分以及消费品、生物技术和制药产品如何改变微生物和宿主生物标志物，推动皮肤健康领域的创新，利用其专有的非侵入性测试平台。其测试平台有助于将复杂的生物数据转化为清晰、可操作的见解。

By integrating microbial and molecular analyses, Sequential enables the development of credible, effective, and trustworthy products and claims..

通过整合微生物和分子分析，Sequential 能够开发出可信、有效且值得信赖的产品和声明。

The company has built one of the most comprehensive clinical datasets in the industry, comprising over 50,000 samples, 4,000+ ingredients, and 10,000+ participants worldwide. The newly raised capital will support the development of an AI-powered discovery engine built on Sequential's proprietary real-world clinical dataset, enabling the prediction, optimisation and discovery of next-generation active complexes and novel bioactive ingredients..

该公司已经建立了行业内最全面的临床数据集之一，包含超过50,000个样本、4,000多种成分以及全球10,000多名参与者。新筹集的资金将用于支持开发一个基于Sequential专有真实世界临床数据集的AI驱动发现引擎，该引擎能够预测、优化并发现下一代活性复合物和新型生物活性成分。

'Our mission is to bring pharmaceutical-grade evidence and computational precision to personal care,' said Oliver Worsley, PhD, CEO and Co-Founder of Sequential. 'By applying artificial intelligence to one of the world's largest clinical datasets in dermatological health, we can both discover new skin biomarkers, and move beyond incremental formulation improvements and instead systematically design and validate breakthrough ingredient combinations.

“我们的使命是将制药级证据和计算精度引入个人护理领域，”Sequential首席执行官兼联合创始人奥利弗·沃斯利博士表示，“通过将人工智能应用于全球最大的皮肤病健康临床数据集之一，我们不仅可以发现新的皮肤生物标志物，而且可以超越渐进式的配方改进，转而系统地设计和验证突破性的成分组合。”

This investment allows us to scale that vision.'.

这项投资使我们能够扩大这一愿景。

Anouk Veber, Ventures' Business Unit Leader in Sparkfood, commented: 'Sequential has built a unique bridge between biology, clinical validation, and consumer product development, linking molecular and microbial biomarkers to real-world product performance. We believe their AI-driven platform will reshape how next-generation personal care products are developed and differentiated.

安努克·韦伯（Anouk Veber），Sparkfood旗下Ventures事业部负责人评论道：“Sequential在生物学、临床验证和消费品开发之间搭建了一座独特的桥梁，将分子和微生物生物标志物与现实世界的产品性能联系起来。我们相信他们的人工智能驱动平台将会重塑下一代个人护理产品的开发和差异化方式。”

This investment also aligns with Sparkfood's connected innovation strategy, opening the door to co-development opportunities and commercial synergies in the personal care space.'.

这项投资也符合Sparkfood的连接创新战略，为个人护理领域的共同开发机会和商业协同效应打开了大门。

Hidehiko Otake, CEO of Corundum Systems Biology, stated: 'Sequential's mission aligns with ours: to transform human health with the power of large datasets, the microbiome, and artificial intelligence. Our continued support in this round reflects our confidence in their vision and our shared commitment to redefining the future of personal care.'.

Corundum Systems Biology 首席执行官 Hidehiko Otake 表示：“Sequential 的使命与我们的一致：利用大型数据集、微生物组和人工智能的力量来变革人类健康。我们在此轮融资中的持续支持反映了我们对他们愿景的信心，以及我们对重新定义个人护理未来的共同承诺。”

By combining systems biology, clinical research infrastructure, and advanced computational modelling, Sequential aims to set a new standard for data-driven innovation in personal care and adjacent health categories. The company will continue expanding its biomarker discovery programs and global partnerships as it builds a scalable discovery engine designed to unlock the next generation of scientifically validated complexes..

通过结合系统生物学、临床研究基础设施和先进的计算建模，Sequential 旨在为个人护理及相邻健康领域设立数据驱动创新的新标准。该公司将继续扩展其生物标志物发现计划和全球合作伙伴关系，同时构建一个可扩展的发现引擎，旨在解锁下一代经过科学验证的复合物。

About Sequential

关于顺序

Sequential

顺序的

is a global leader in the skin microbiome field, a team of PhD experts in testing products and their effect on human health. An Innovate UK- and Enterprise Singapore-backed company, with labs in Cambridge, New York City and Singapore. Awarded the title 'Most Significant' Testing Solution in the Industry - (C&T, 2022).

是皮肤微生物组领域的全球领导者，拥有一支由博士专家组成的团队，专注于测试产品及其对人类健康的影响。这是一家得到英国创新署（Innovate UK）和新加坡企业发展局（Enterprise Singapore）支持的公司，在剑桥、纽约和新加坡设有实验室。荣获行业“最具意义”测试解决方案称号（《化妆品与技术》2022年）。

To date, Sequential has amassed over 50,000 human skin microbiome samples and corresponding formulations tested in vivo on the skin. With this vast genomic dataset, Sequential is innovating in inflammatory disease areas, for example – acne, atopic dermatitis and rosacea. They have been previously supported by Innovate UK, Enterprise SG, A*STAR (Genome Institute of Singapore), SOSV, Corundum Systems Biology and other leading organisations..

迄今为止，Sequential 已收集了超过 50,000 个人类皮肤微生物组样本，并在皮肤上进行了相应的体内测试配方。凭借这一庞大的基因组数据集，Sequential 正在炎症性疾病领域进行创新，例如痤疮、特应性皮炎和玫瑰痤疮。他们此前曾得到 Innovate UK、Enterprise SG、A*STAR（新加坡基因组研究所）、SOSV、Corundum Systems Biology 和其他领先组织的支持。

www.sequential.bio

www.sequential.bio

Photo -

照片 -

https://mma.prnewswire.com/media/2925157/Sequential.jpg

https://mma.prnewswire.com/media/2925157/Sequential.jpg

21

21

%

%

more press release views with

更多新闻发布观点

Request a Demo

请求演示